International Journal of Cancer Management

Published by: Kowsar

Evaluation of Survival Rate and Non-Fetal Outcomes in Patients with Esophageal Cancer Under Treatment with Neoadjuvant Chemoradiotherapy Plus Additional Platinium-Based Chemotherapy from 2010 to 2016

Hasan Ali Vahedian ORCID 1 , Mohsen Akhondi-Meybodi ORCID 1 , * , Fatemeh Mansouri 1 , ** and Masoud Shabani 1
Authors Information
1 Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
Corresponding Authors:
Article information
  • International Journal of Cancer Management: June 30, 2019, 12 (6); e89003
  • Published Online: June 17, 2019
  • Article Type: Research Article
  • Received: January 10, 2019
  • Revised: June 3, 2019
  • Accepted: June 8, 2019
  • DOI: 10.5812/ijcm.89003

To Cite: Vahedian H A , Akhondi-Meybodi M, Mansouri F , Shabani M . Evaluation of Survival Rate and Non-Fetal Outcomes in Patients with Esophageal Cancer Under Treatment with Neoadjuvant Chemoradiotherapy Plus Additional Platinium-Based Chemotherapy from 2010 to 2016, Int J Cancer Manag. 2019 ; 12(6):e89003. doi: 10.5812/ijcm.89003.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210. [PubMed: 25220842].
  • 2. Keighley MRB. Gastrointestinal cancers in Europe. Aliment Pharmacol Ther. 2003;18(s3):7-30. doi: 10.1046/j.0953-0673.2003.01722.x.
  • 3. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, et al. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog. 2006;45(8):613-26. doi: 10.1002/mc.20193. [PubMed: 16788983]. [PubMed Central: PMC1899163].
  • 4. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556-63. doi: 10.1093/annonc/mdn642. [PubMed: 19073863].
  • 5. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8(6):545-53. doi: 10.1016/S1470-2045(07)70172-9. [PubMed: 17540306].
  • 6. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015;13(2):194-227. [PubMed: 25691612].
  • 7. Berry MF. Esophageal cancer: staging system and guidelines for staging and treatment. J Thorac Dis. 2014;6 Suppl 3:S289-97. doi: 10.3978/j.issn.2072-1439.2014.03.11. [PubMed: 24876933]. [PubMed Central: PMC4037413].
  • 8. Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M, et al. Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients. Oncol Rep. 2012;28(2):446-52. doi: 10.3892/or.2012.1847. [PubMed: 22664791]. [PubMed Central: PMC3583592].
  • 9. Liu B, Bo Y, Wang K, Liu Y, Tang X, Zhao Y, et al. Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials. Oncotarget. 2017;8(12):20410-7. doi: 10.18632/oncotarget.14669. [PubMed: 28099899]. [PubMed Central: PMC5386772].
  • 10. Thies S, Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol. 2013;3:262. doi: 10.3389/fonc.2013.00262. [PubMed: 24109590]. [PubMed Central: PMC3791673].
  • 11. Malekzade R, Semnani SH, Sajadi A. [Esophagus cancer in Iran]. Govaresh. 2008;13(10):25-34. Persian.
  • 12. Hosseini A, SharifZade L, SaiehMiri K, Mortazavi Tabatabaii A. [Survey of esophageal cancer in Iran: A systematic review and meta-analysis]. Res Med J. 2011;36(1):43-9. Persian.
  • 13. Sadjadi A, Marjani H, Semnani S, Nasseri-Moghaddam S. Esophageal Cancer in Iran: A Review. Middle East J Cancer. 2010;1(1):5-14.
  • 14. Babaei M. Survival rate of gastric and esophageal cancers in Ardabil province, North-West of Iran. Eur J Cancer Suppl. 2008;6(9):161. doi: 10.1016/s1359-6349(08)71794-4.
  • 15. Samadi F, Babaei M, Yazdanbod A, Fallah M, Nouraie M, Nasrollahzadeh D, et al. Survival rate of gastric and esophageal cancers in Ardabil province, North-West of Iran. Arch Iran Med. 2007;10(1):32-7. [PubMed: 17198451].
  • 16. Hajian-Tilaki KO. Factors affecting the survival of patients with oesophageal carcinoma under radiotherapy in the north of Iran. Br J Cancer. 2001;85(11):1671-4. doi: 10.1054/bjoc.2001.2153. [PubMed: 11742486]. [PubMed Central: PMC2363975].
  • 17. Nourafkan Z, Yavari P, Roshandel GH, Khalili D, Behnampour N, Zayeri F. [Estimation of survival rate of esophageal cancer and some of its determinants in Golestan province, north of Iran]. Iran J Epidemiol. 2013;9(1):11-8. Persian.
  • 18. Aghcheli K, Marjani HA, Nasrollahzadeh D, Islami F, Shakeri R, Sotoudeh M, et al. Prognostic factors for esophageal squamous cell carcinoma--a population-based study in Golestan Province, Iran, a high incidence area. PLoS One. 2011;6(7). e22152. doi: 10.1371/journal.pone.0022152. [PubMed: 21811567]. [PubMed Central: PMC3141005].
  • 19. Schena M, La Rovere E, Solerio D, Bustreo S, Barone C, Daniele L, et al. Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: a monocentric study. Tumori. 2012;98(4):451-7. doi: 10.1700/1146.12639. [PubMed: 23052161].
  • 20. Nabavizadeh N, Shukla R, Elliott DA, Mitin T, Vaccaro GM, Dolan JP, et al. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy. Dis Esophagus. 2016;29(6):614-20. doi: 10.1111/dote.12377. [PubMed: 26043837].
  • 21. Suzuki G, Yamazaki H, Ogo E, Abe T, Eto H, Muraki K, et al. Multimodal approach for cervical esophageal carcinoma: role of neoadjuvant chemotherapy. Anticancer Res. 2014;34(4):1989-92. [PubMed: 24692736].
  • 22. Ordu AD, Nieder C, Geinitz H, Kup PG, Deymann LF, Scherer V, et al. Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus: long-term outcome. Strahlenther Onkol. 2015;191(2):153-60. doi: 10.1007/s00066-014-0779-x. [PubMed: 25404062].
  • 23. Kim YH, Song SY, Shim HJ, Chung WK, Ahn SJ, Yoon MS, et al. Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer. Radiat Oncol J. 2015;33(1):12-20. doi: 10.3857/roj.2015.33.1.12. [PubMed: 25874173]. [PubMed Central: PMC4394064].
  • 24. Hamai Y, Hihara J, Emi M, Murakami Y, Kenjo M, Nagata Y, et al. Results of neoadjuvant chemoradiotherapy with docetaxel and 5-fluorouracil followed by esophagectomy to treat locally advanced esophageal cancer. Ann Thorac Surg. 2015;99(6):1887-93. doi: 10.1016/j.athoracsur.2015.02.042. [PubMed: 25912745].
  • 25. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol. 2006;32(1):55-64. doi: 10.1016/j.ejso.2005.09.010. [PubMed: 16324817].
  • 26. Meguid RA, Hooker CM, Taylor JT, Kleinberg LR, Cattaneo SM, 2nd, Sussman MS, et al. Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg. 2009;138(6):1309-17. doi: 10.1016/j.jtcvs.2009.07.069. [PubMed: 19931663]. [PubMed Central: PMC3654695].
  • 27. Alnaji RM, Du W, Gabriel E, Singla S, Attwood K, Nava H, et al. Pathologic complete response is an independent predictor of improved survival following neoadjuvant chemoradiation for esophageal adenocarcinoma. J Gastrointest Surg. 2016;20(9):1541-6. doi: 10.1007/s11605-016-3177-0. [PubMed: 27260525].
  • 28. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol. 2006;78(3):236-44. doi: 10.1016/j.radonc.2006.01.009. [PubMed: 16545878].
  • 29. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23(19):4330-7. doi: 10.1200/JCO.2005.05.017. [PubMed: 15781882].
  • 30. Zhu LL, Yuan L, Wang H, Ye L, Yao GY, Liu C, et al. A meta-analysis of concurrent chemoradiotherapy for advanced esophageal cancer. PLoS One. 2015;10(6). e0128616. doi: 10.1371/journal.pone.0128616. [PubMed: 26046353]. [PubMed Central: PMC4457836].
  • 31. Anvari K, Al davud A, Noferesti GH, Sedighi A, Mohtashami S. [Treatment of esophageal cancer using combination chemotherapy and radiotherapy before surgery]. Med J Mashhad Unive Med Sci. 2009;52(3):173-9. Persian. doi: 10.22038/mjms.2009.5434.
  • 32. Moghimi Dehkordi B, Rajaie fard A, Tabatabaie SH, Zeighami B, Safaie A, Tabeie SZ. [Survival prognostic factors in patients with esophageal cancer registered in Fars Cancer Registry Center]. Iran South Med J. 2009;11(2):177-82. Persian.
  • 33. Thoen H, Ceelen W, Boterberg T, Van Daele E, Pattyn P. Tumor recurrence and in-field control after multimodality treatment of locally advanced esophageal cancer. Radiother Oncol. 2015;115(1):16-21. doi: 10.1016/j.radonc.2015.03.012. [PubMed: 25818394].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments